-
Huadong Medicine awarded South Korean company Daewon company oral small molecule GLP-1R agonist development rights
Time of Update: 2021-10-10
In 2017, Huadong Medicine authorized the exclusive development, production and commercialization rights of 16 Asia-Pacific countries and regions including China and South Korea from vTv Therapeutics of the United States .
Huadong Medicine is currently conducting Phase 2 clinical trials of TTP273 in China and Taiwan .
-
Nuocheng Jianhua's new drug ICP-723 is selected as one of the 100 new technologies and new products of the Zhongguancun Forum in 2021
Time of Update: 2021-10-10
Beijing, September 29, 2021/PRNewswire/ - Biomedical high-tech company Nuocheng Jianhua (Hong Kong Stock Exchange code: 09969) today announced that the company's self-developed second-generation pan-TRK inhibitor ICP-723 has been selected 2021 Zhongguancun International Technology Trade Conference 100 new technologies and new products list .
-
Beijing Jishuitan Hospital held the unveiling ceremony of the Wound Repair Center!
Time of Update: 2021-10-10
The scope of diagnosis and treatment of the Burn Plastic Surgery Department and Wound Repair Center mainly includes Treatment of burns of various reasons: large-area severe burns, scalds, explosive compound injuries, inhalation injuries, medium and small-area burns, scalds, frostbite, electric burns, chemical burns (sulfuric acid, hydrochloric acid, aqua regia, caustic soda), heat Treatment of various types of burns such as crush injuries and thermomechanical combined injuries .
-
A batch of chain pharmacies have sold certificates and withdrew from the market!
Time of Update: 2021-10-10
On September 26, the Drug Administration of Ningxia Hui Autonomous Region issued the "Notice on the cancellation of the "Pharmaceutical Business License" of Guyuan Ruihetang Pharmaceutical Chain Sales Co.
-
Yuli Pharmaceutical won the 2021 Sustainability Platinum Award from EcoVadis
Time of Update: 2021-10-10
Singapore, October 6, 2021/PRNewswire/ - Zuellig Pharma, Asia's leading healthcare service provider, won the 2021 Platinum Award from EcoVadis, a professional sustainability rating agency .
Our employees provide services to more than 350,000 medical institutions and have established cooperation with more than 1,000 customers, including the world's top 20 pharmaceutical companies .
-
How far is TCM from internationalization?
Time of Update: 2021-10-10
Authors: Liu Shujing, Li ChenshuoThe overseas innovative development of Chinese medicine is an important path to inherit and promote the excellent Chinese traditional culture, and it is also the core
-
Kanghua Animal Health will open up the "last mile" of rabies prevention
Time of Update: 2021-10-10
"Human use + pet use" high-quality vaccines help promote immunityHow to better respond to the national rabies prevention and control plan and promote the progress of animal immunization, the key lies in the development and production of high-quality animal vaccines .
-
The fifth domestic PD-L1 monoclonal antibody will be declared for listing
Time of Update: 2021-10-10
, has been approved by the CDE to submit an application for the listing of a new drug for the treatment of recurrent or metastatic cervical cancer, the anti-PD-L1 monoclonal antibody Socazolimab (R&D code: ZKAB001) .
-
Under the accelerated transformation and upgrading of the pharmaceutical industry, how does the pharmaceutical machinery industry fight a "cooperation war"
Time of Update: 2021-10-10
It is worth noting that in recent years, with the increasing aging of our country, the continuous improvement of residents' living standards, and the advancement of medical reform, the domestic pharmaceutical market has ushered in rapid development, while industrial transformation and upgrading have also begun to accelerate .
-
Over 30 new drugs approved in China in the third quarter of 2021!
Time of Update: 2021-10-10
At the same time, a number of new anti-cancer drugs were approved in China for the first time, including the second-generation proteasome inhibitor carfilzomib jointly developed by Amgen and BeiGene, and anti-GD2 introduced by BeiGene from EUSA Pharma.
-
Various places are vigorously promoting the development of the biomedical industry, and this market may usher in a big explosion!
Time of Update: 2021-10-10
In addition to Jiangsu Province, the Hainan Provincial Food and Drug Administration has also issued the "Notice on Further Optimizing Services to Support the High-Quality Development of the Biopharmaceutical Industry", and introduced a total of 12 optimization service measures, from promoting the development of industrial clusters and encouraging the undertaking of the production of pharmaceuticals and medical devices.
-
Hengrui's Fluzoparib is approved for clinical treatment of colorectal cancer with bevacizumab
Time of Update: 2021-10-10
On September 28, Hengrui Medicine announced that the PARP inhibitor fluzoparib has been approved for a phase Ib/III clinical trial, combined with bevacizumab versus capecitabine and bevacizumab for unresectable or metastatic disease First-line maintenance treatment for colorectal cancer .
-
Will taking antihypertensive drugs be resistant?
Time of Update: 2021-10-10
The blood pressure control of a certain drug is related to the patient's age, compliance, eating habits and other factors .
-
The State Food and Drug Administration issued technical guidelines for clinical trials of new in vitro diagnostic reagents
Time of Update: 2021-10-10
The plan shall make clear provisions on the type of trial design, selection of comparison methods, selection of subjects, evaluation indicators, statistical analysis methods, sample size estimation and quality control requirements, etc.
-
With the rapid development of innovative drugs, investors are increasingly concerned about whether pharmaceutical companies have the ability to "go global"
Time of Update: 2021-10-10
Analysts said that there are more and more products and clinical trials of innovative drugs in China and the United States, which is a general trend .
-
Syndrome differentiation and treatment, three-in-one system of TCM remote consultation to assist in the diagnosis and treatment of new coronary cases in Fujian
Time of Update: 2021-10-10
Chinanews At the scene, Li Candong, President of Fujian University of Traditional Chinese Medicine, Lin Haibin, Secretary of the Party Committee of the Affiliated Hospital of Putian University, relevant persons in charge of the Third People's Hospital Affiliated to Fujian University of Traditional Chinese Medicine, and experts from Fujian University of Traditional Chinese Medicine, Fujian Traditional Chinese Medicine Anti-epidemic Aid Medical Team, and Affiliated Hospital of Putian University Attend the consultation .
-
The three quarterly reports surfaced, which one in the pharmaceutical and biological industry is happy and which one is worried?
Time of Update: 2021-10-10
Yan'an Bikang said that the new energy products of Jiujiujiu Technology, its subsidiary, were affected by market demand, the release of production capacity, and the increase in market prices, resulting in an increase in profits over the same period last year, which played a positive role in promoting the company's performance growth .
-
Hengrui counterattacks Yangtze River!
Time of Update: 2021-10-10
Can Hengrui take this advantage to return to its high position?Picture 1: Hengrui's latest product declarationSource: CDE official websiteFigure 2: Changes in the share of dexmedetomidine hydrochloride injection TOP3 companiesSource: Mi Nei. com, China's public medical institutions terminal competition patternDexmedetomidine is an α2 adrenergic receptor agonist, mainly used for tracheal intubation and sedation during mechanical ventilation in patients undergoing general anesthesia .
-
With the continued positive development of the pharmaceutical packaging industry, this type of enterprise has a broad market prospect
Time of Update: 2021-10-10
From the perspective of development trends, China is currently continuously introducing and upgrading pharmaceutical packaging equipment and materials, and the entire industry is showing a brand new situation .
-
2 Qilu Class 1 biological drugs are coming!
Time of Update: 2021-10-10
On September 28, CDE's official website showed that Qilu Pharmaceutical's QLF32004 and QLP31907 injections for class 1 biological drug injections have obtained the implied license of clinical trials and are intended to be used for the treatment of advanced malignant solid tumors and B-cell malignant tumors .
